29 Apr
2021

Hatch-Waxman litigation defendants get taxation boost

This week’s ruling in Mylan v Commissioner of Revenue suggests generic drug companies will be able to count their ANDA litigation costs as deductible expenses, reversing established tax rules.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth